EP0493496A1 - Ibuprofen triturates and topical compositions containing same - Google Patents

Ibuprofen triturates and topical compositions containing same

Info

Publication number
EP0493496A1
EP0493496A1 EP90914743A EP90914743A EP0493496A1 EP 0493496 A1 EP0493496 A1 EP 0493496A1 EP 90914743 A EP90914743 A EP 90914743A EP 90914743 A EP90914743 A EP 90914743A EP 0493496 A1 EP0493496 A1 EP 0493496A1
Authority
EP
European Patent Office
Prior art keywords
ibuprofen
composition
menthol
topical
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90914743A
Other languages
German (de)
French (fr)
Inventor
John Francis 13 Charter Drive Smith
Donald Peter 12 Marlesford Close Vaughan
Kenneth Murray August Field Henderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mentholatum Co Ltd
Original Assignee
Mentholatum Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mentholatum Co Ltd filed Critical Mentholatum Co Ltd
Publication of EP0493496A1 publication Critical patent/EP0493496A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Definitions

  • the present invention relates to topical ibuprofen formulations.
  • Ibuprofen ie. (isobutyl phenyl)propionic acid
  • Ibuprofen is a white crystalline drug, insoluble in water but relatively soluble in organic solvents such as alcohol (1 in 1.5); chloroform (1 in 1) ; ether (1 in 2) and acetone (1 in 1.5) .
  • Ibuprofen usually is taken orally and, although a number of topical formulations have been proposed, we are not aware of any satisfactory topical formulations. However, it often would be preferred to administer ibuprofen by topical application to an affected area so as to permit absorption through the skin. For example, in the treatment of rheumatic pain and/or inflammation, it is desirable to sustain a high local concentration of ibuprofen in the affected area of the body. Whereas oral administration to provide such local concentration would result in unacceptably high concentrations of ibuprofen throughout the body, topical application allows ibuprofen to accumulate only where it is needed. In this connection, it is believed that solution dosage forms offer the best prospects of efficient percutaneous absorption of ibuprofen from topical formulations.
  • the present Applicants have experimented with topical formulations using conventional vehicles containing long chain cetyl and stearyl alcohols. They found that ibuprofen appears to react with these alcohols, thus reducing the concentration of the active ingredient for absorption. There was also a marked tendency for the ibuprofen to crystallise on storage as described above. Mineral and vegetable oils dissolve ibuprofen but, even at very high oil concentrations, the ibuprofen soon crystallises out. Oleic acid also dissolves ibuprofen but the solution has an unpleasant smell and is sticky and liable to autoxidation.
  • Vehicles based on combinations of oleic acid and medium chain length oils were investigated with various emulsifying agents - but avoiding cetyl and stearyl alcohols. These combinations prevented ibuprofen from crystallising out of an organic solution, but the emulsion formed could not be stiffened or settled sufficiently to withstand storage at 35 to 37°C for several months. Further, the H.L.B. (ie. hydrophilic-lipophilic balance) was higher than considered desirable for topical use.
  • Menthol ie. 2-isopropyl-5-methylcyclohexanol
  • Menthol is a crystalline, naturally-occurring substance which has been used in pharmacy for at least a century. It has a penetrating odour and, for that reason, is widely used to relieve symptoms of bronchitis, sinusitis and similar conditions. It is used as an adjuvant in a number of topical formulations and has been reported to enhance the percutaneous transfer of systemically active, water- soluble or solubilizable drugs (see EP-A-0147146) .
  • JP-A-63179820 discloses that the bioavailability of water-soluble pharmacological agents in suppository preparations can be increased by adding the agent to the suppository base as a solution in a mixture of menthol and camphor. Ibuprofen is included in the list of specified agents.
  • ibuprofen and menthol both crystalline substances form a co-solution when mixed together. Whilst not wishing to be bound to any particular theory, it is believed that the two substances form a co-solution or eutectic solution when so mixed. Depending upon the relative proportions of the two components, one or both may be present partially in microcrystalline form.
  • co-solution mixtures of ibuprofen and menthol can be formed in situ by mixing ibuprofen and menthol together with other components of a topical composition.
  • the present invention provides a composition comprising a co-solution mixture of ibuprofen and menthol.
  • the invention further provides a topical pharmaceutical composition containing said mixture in a pharmacologically acceptable vehicle and the use of menthol to stabilize a topical composition comprising ibuprofen.
  • a liquid triturate can be formed by triturating the ibuprofen, menthol and optionally other components at ambient temperature and the triturate added to a vehicle to form the topical pharmaceutical composition of the invention.
  • the triturate could be formed by heating the components together whilst triturating or by stirring or otherwise mixing a fused mass of the components and then cooling the hot mixture.
  • the components can be compounded by dissolution in a suitable solvent, such as ethanol and the resultant solution (containing the co-solution mixture) added to the vehicle.
  • any relative proportions of ibuprofen and menthol which provide a co-solution mixture which is liquid at ambient temperature can be used.
  • the amount of ibuprofen by weight will be 10 to 70 percent based upon the weight of said mixture.
  • said amount of ibuprofen preferably is 50 to 70 percent by weight.
  • Part of the menthol can be replaced by benzyl alcohol. When benzyl alcohol is present, it usually will replace 10 to 80, preferably 25 to 60, weight percent of the menthol.
  • a pharmaceutically acceptable alcohol especially a glycol such as propylene glycol or a Macrogol (ie. polyethylene glycol) in the liquid triturate of the invention when it is to be used to formulate a topical gel.
  • a triturate contains a glycol, it usually will be present in an amount by weight of up to 30 percent of the triturate. Preferably, said amount is 10 to 30 percent by weight and especially 20 to 25 percent by weight.
  • substantially more glycol eg. up to 70 percent by weight of the combined weight of ibuprofen, menthol, glycol and, if present, benzyl alcohol can be used when formulating a topical composition via a solution as mentioned above.
  • the liquid triturate or other co-solution mixture can be admixed with any compatible pharmacologically acceptable vehicle to form a topical composition.
  • vehicle is an aqueous gel or cream.
  • Carbomer ie. carboxypolymethylene; carboxyvinyl polymer
  • the concentration of ibuprofen in the topical compositions of the invention will be in the range 0.1 to 20 percent by weight but any pharmacologically active concentration can be used.
  • the ibuprofen concentration will be 2 to 12 percent by weight and especially 3 to 6 percent by weight. Said amounts are by weight based upon the total weight of the topical composition.
  • topical compositions of the invention can contain other compatible pharmacologically acceptable additives conventionally used in topical formulations such as antimicrobial agents, colorants, perfumes, Ph modifiers, antioxidant ⁇ and stabilisers. Further, they can contain other compatible pharmacologically active substances such as other non-steroidal anti-inflammatory agents, steroids, antibiotics and antibacterials.
  • Crystalline ibuprofen was triturated with 1.5 g crystalline menthol to form an oil phase. This oil phase was then mixed with propylene glycol and then added to a second gel of Carbomer, ethanol and water to form a topical gel having the following composition:
  • the gel was cloudy in appearance and, under the microscope was seen to contain dispersed microcrystalline material.
  • Ibuprofen, menthol and propylene glycol were mixed together in ethanol and the resultant solution mixed with an aqueous Carbomer gel and subsequently thickened with- triethanolamine to provide a topical gel of the same composition as that of Example 5.

Abstract

L'ibuprofène forme un mélange de co-solution qui peut être mélangé à un véhicule pour former une composition topique stable. Une part du menthol peut être remplacée par de l'alcool benzoïque et le mélange peut aussi comprendre un alcool pharmacologiquement acceptable, notamment glycol de propylène.Ibuprofen forms a co-solution mixture which can be mixed with a vehicle to form a stable topical composition. Part of the menthol can be replaced by benzoic alcohol and the mixture can also comprise a pharmacologically acceptable alcohol, in particular propylene glycol.

Description

(Case 1)
IBUPROFEN TRITURATES AND TOPICAL COMPOSITIONS
CONTAINING SAME
The present invention relates to topical ibuprofen formulations.
Ibuprofen (ie. (isobutyl phenyl)propionic acid) is a white crystalline drug, insoluble in water but relatively soluble in organic solvents such as alcohol (1 in 1.5); chloroform (1 in 1) ; ether (1 in 2) and acetone (1 in 1.5) .
Ibuprofen usually is taken orally and, although a number of topical formulations have been proposed, we are not aware of any satisfactory topical formulations. However, it often would be preferred to administer ibuprofen by topical application to an affected area so as to permit absorption through the skin. For example, in the treatment of rheumatic pain and/or inflammation, it is desirable to sustain a high local concentration of ibuprofen in the affected area of the body. Whereas oral administration to provide such local concentration would result in unacceptably high concentrations of ibuprofen throughout the body, topical application allows ibuprofen to accumulate only where it is needed. In this connection, it is believed that solution dosage forms offer the best prospects of efficient percutaneous absorption of ibuprofen from topical formulations.
The present Applicants have experimented with topical formulations using conventional vehicles containing long chain cetyl and stearyl alcohols. They found that ibuprofen appears to react with these alcohols, thus reducing the concentration of the active ingredient for absorption. There was also a marked tendency for the ibuprofen to crystallise on storage as described above. Mineral and vegetable oils dissolve ibuprofen but, even at very high oil concentrations, the ibuprofen soon crystallises out. Oleic acid also dissolves ibuprofen but the solution has an unpleasant smell and is sticky and liable to autoxidation. Vehicles based on combinations of oleic acid and medium chain length oils were investigated with various emulsifying agents - but avoiding cetyl and stearyl alcohols. These combinations prevented ibuprofen from crystallising out of an organic solution, but the emulsion formed could not be stiffened or settled sufficiently to withstand storage at 35 to 37°C for several months. Further, the H.L.B. (ie. hydrophilic-lipophilic balance) was higher than considered desirable for topical use.
Menthol (ie. 2-isopropyl-5-methylcyclohexanol) is a crystalline, naturally-occurring substance which has been used in pharmacy for at least a century. It has a penetrating odour and, for that reason, is widely used to relieve symptoms of bronchitis, sinusitis and similar conditions. It is used as an adjuvant in a number of topical formulations and has been reported to enhance the percutaneous transfer of systemically active, water- soluble or solubilizable drugs (see EP-A-0147146) .
It has long been known that trituration of menthol with certain other crystalline substances, such as camphor (ie. l,7,7-trimethylbicyclo(2,2,l)heptan-2-one) , chloral hydrate (ie. 2,2,2-trichloroethane-l,l-diol) and phenol, forms a co-solution liquid or soft mass. However, we are not aware of any disclosure of trituration or admixture of menthol with a propionic acid derivative or of any other disclosure which would have led those skilled in the art of topical formulations to consider the use of menthol to overcome the problem of topically formulating ibuprofen. JP-A-63179820 discloses that the bioavailability of water-soluble pharmacological agents in suppository preparations can be increased by adding the agent to the suppository base as a solution in a mixture of menthol and camphor. Ibuprofen is included in the list of specified agents.
It has now surprisingly been found that ibuprofen and menthol (both crystalline substances) form a co-solution when mixed together. Whilst not wishing to be bound to any particular theory, it is believed that the two substances form a co-solution or eutectic solution when so mixed. Depending upon the relative proportions of the two components, one or both may be present partially in microcrystalline form.
The use of such a co-solution in a topical pharmaceutical composition leads to improved stability. Further, co-solution mixtures of ibuprofen and menthol can be formed in situ by mixing ibuprofen and menthol together with other components of a topical composition.
It also has been found that the amount of menthol required to provide a co-solution with ibuprofen can be reduced by the presence of benzyl alcohol as a co-solvent for the ibuprofen. The present invention provides a composition comprising a co-solution mixture of ibuprofen and menthol. The invention further provides a topical pharmaceutical composition containing said mixture in a pharmacologically acceptable vehicle and the use of menthol to stabilize a topical composition comprising ibuprofen.
A liquid triturate can be formed by triturating the ibuprofen, menthol and optionally other components at ambient temperature and the triturate added to a vehicle to form the topical pharmaceutical composition of the invention. However, the triturate could be formed by heating the components together whilst triturating or by stirring or otherwise mixing a fused mass of the components and then cooling the hot mixture. Alternatively, the components can be compounded by dissolution in a suitable solvent, such as ethanol and the resultant solution (containing the co-solution mixture) added to the vehicle.
Any relative proportions of ibuprofen and menthol which provide a co-solution mixture which is liquid at ambient temperature can be used. Suitably, the amount of ibuprofen by weight will be 10 to 70 percent based upon the weight of said mixture. However, said amount of ibuprofen preferably is 50 to 70 percent by weight. Part of the menthol can be replaced by benzyl alcohol. When benzyl alcohol is present, it usually will replace 10 to 80, preferably 25 to 60, weight percent of the menthol.
It is preferred to include a pharmaceutically acceptable alcohol, especially a glycol such as propylene glycol or a Macrogol (ie. polyethylene glycol) in the liquid triturate of the invention when it is to be used to formulate a topical gel. When a triturate contains a glycol, it usually will be present in an amount by weight of up to 30 percent of the triturate. Preferably, said amount is 10 to 30 percent by weight and especially 20 to 25 percent by weight. However, substantially more glycol, eg. up to 70 percent by weight of the combined weight of ibuprofen, menthol, glycol and, if present, benzyl alcohol can be used when formulating a topical composition via a solution as mentioned above. The liquid triturate or other co-solution mixture can be admixed with any compatible pharmacologically acceptable vehicle to form a topical composition. Preferably, the vehicle is an aqueous gel or cream. Carbomer (ie. carboxypolymethylene; carboxyvinyl polymer) is particularly suitable as a gelling agent in said aqueous gel vehicle.
Usually, the concentration of ibuprofen in the topical compositions of the invention will be in the range 0.1 to 20 percent by weight but any pharmacologically active concentration can be used. Preferably, the ibuprofen concentration will be 2 to 12 percent by weight and especially 3 to 6 percent by weight. Said amounts are by weight based upon the total weight of the topical composition.
The topical compositions of the invention can contain other compatible pharmacologically acceptable additives conventionally used in topical formulations such as antimicrobial agents, colorants, perfumes, Ph modifiers, antioxidantε and stabilisers. Further, they can contain other compatible pharmacologically active substances such as other non-steroidal anti-inflammatory agents, steroids, antibiotics and antibacterials.
The present invention is illustrated by the following non-limiting examples.
EXAMPLE 1
4 g Crystalline ibuprofen was triturated with 4 g crystalline menthol to form an oil phase. This oil phase was then mixed with Carbomer, ethanol and water to form a topical gel having the following composition:
* Carbopol 941
EXAMPLE 2
4 g Crystalline ibuprofen was triturated with 4 g crystalline menthol and 5 g propylene glycol to form an oil phase, which was then mixed with Carbomer, ethanol and water to form a topical gel having the following composition:
* Carbopol 941
EXAMPLE 3
4 g Crystalline ibuprofen was triturated with 4 g crystalline menthol, 3 g propylene glycol and 3 g benzyl alcohol to form an oil phase, which was then mixed with Carbomer, ethanol and water to form a topical gel having the following composition.
* Carbopol 941
EXAMPLE 4
4 g Crystalline ibuprofen was triturated with 2 g crystalline menthol, 4 g propylene glycol and 4 g benzyl alcohol to form an oil phase, which was then mixed with Carbomer, ethanol and water to form a topical gel having the following composition. Ibuprofen 4 g
Menthol 2 g
Propylene glycol 4 g
Benzyl alcohol 4 g
Carbomer* 1-2 g
Ethanol qs
Water to 100 g
* Carbopol 941
EXAMPLE 5
3.0 g Crystalline ibuprofen was triturated with 1.5 g crystalline menthol to form an oil phase. This oil phase was then mixed with propylene glycol and then added to a second gel of Carbomer, ethanol and water to form a topical gel having the following composition:
* Carbopol 980
The gel was cloudy in appearance and, under the microscope was seen to contain dispersed microcrystalline material.
EXAMPLE 6
Ibuprofen, menthol and propylene glycol were mixed together in ethanol and the resultant solution mixed with an aqueous Carbomer gel and subsequently thickened with- triethanolamine to provide a topical gel of the same composition as that of Example 5.
The gels of Examples 1 to 6 were found to be completely stable after storage for 6 months at ambient temperatures. At the end of the period of storage there was no significant loss of dissolved ibuprofen through crystallisation.

Claims

CLAIMS:
1. A composition comprising a co-solution mixture of ibuprofen and menthol.
2. A topical pharmaceutical composition comprising a co- solution mixture of ibuprofen and menthol in a pharmacologically acceptable vehicle.
3. A topical composition as claimed in Claim 2, wherein the vehicle is an aqueous gel.
4. A topical composition as claimed in Claim 2, wherein the ibuprofen content is 2 to 12 percent by weight of the composition.
5. A topical composition as claimed in Claim 4, wherein said ibuprofen content is 3 to 6 percent by weight of the composition.
6. A composition as claimed in Claim 1, which is a liquid triturate consisting essentially of ibuprofen and menthol.
7. A composition as claimed in Claim 1, comprising benzyl alcohol.
8. A composition as claimed in Claim 7, which is a liquid triturate consisting essentially of ibuprofen, menthol and benzyl alcohol.
9. A composition as claimed in Claim 1, wherein the ibuprofen is present in an amount in the range 50 to 70 percent by weight of the combined weights of ibuprofen, menthol and, if present, benzyl alcohol.
10. A composition as claimed in Claim 1, further comprising a glycol.
11. A composition as claimed in Claim 10, wherein said glycol is propylene glycol.
12. A composition as claimed in Claim 11, which is a liquid triturate consisting essentially of ibuprofen, menthol and propylene glycol.
13. A composition as claimed in Claim 10, wherein the glycol is present in an amount in the range 10 to 70 percent by weight of the combined weights of ibuprofen, menthol, glycol and, if present, benzyl alcohol.
14. A composition as claimed in Claim 13, wherein the amount by weight of glycol is 10 to 30 percent by weight of the triturate.
15. A composition as claimed in Claim 2, comprising ethanol.
16. A method of stabilizing a topical composition comprising ibuprofen which comprises incorporating in said composition an amount of menthol sufficient to form a co- solution mixture with the ibuprofen.
EP90914743A 1989-09-26 1990-09-25 Ibuprofen triturates and topical compositions containing same Withdrawn EP0493496A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8921710 1989-09-26
GB898921710A GB8921710D0 (en) 1989-09-26 1989-09-26 Ibuprofen triturates and topical compositions containing same

Publications (1)

Publication Number Publication Date
EP0493496A1 true EP0493496A1 (en) 1992-07-08

Family

ID=10663631

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90914743A Withdrawn EP0493496A1 (en) 1989-09-26 1990-09-25 Ibuprofen triturates and topical compositions containing same

Country Status (6)

Country Link
EP (1) EP0493496A1 (en)
JP (1) JPH05502440A (en)
AU (1) AU6504190A (en)
CA (1) CA2067131A1 (en)
GB (2) GB8921710D0 (en)
WO (1) WO1991004733A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360938A (en) * 1991-08-21 1994-11-01 Union Carbide Chemicals & Plastics Technology Corporation Asymmetric syntheses
US6344211B1 (en) 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
DE4446600A1 (en) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermal absorption of active ingredients from supercooled melts
AT408067B (en) * 1995-03-17 2001-08-27 Gebro Pharma Gmbh PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION AND METHOD FOR THE PRODUCTION THEREOF
NZ501235A (en) 1997-05-14 2001-06-29 Galen Chemicals Ltd Topical compositions containing emulsion of a discontinuous phase which is an eutectic mixture of two pharmaceutical agents and a continuous phase
US6299902B1 (en) 1999-05-19 2001-10-09 The University Of Georgia Research Foundation, Inc. Enhanced transdermal anesthesia of local anesthetic agents
US6368618B1 (en) * 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
US7197359B1 (en) 1999-10-14 2007-03-27 Pola Chemical Industries Inc. Compositions for electroporation
US7089053B1 (en) 1999-10-14 2006-08-08 Pola Chemical Industries Inc Compositions for drug administration by electroporation
DK1487416T3 (en) 2002-03-26 2010-03-29 Teva Pharma Drug Microparticles
JP2005350379A (en) * 2004-06-09 2005-12-22 Ikeda Mohandou:Kk Method for stabilizing prednisolone valerate acetate and excellently stable skin care preparation for external use comprising prednisolone valerate acetate
US20130072575A1 (en) * 2011-09-19 2013-03-21 Johnson & Johnson Consumer Companies, Inc. Method and Composition for Treating Pain
US11007161B1 (en) 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440777A (en) * 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
JPS5815909A (en) * 1981-07-22 1983-01-29 Toko Yakuhin Kogyo Kk Antimycotic agent for external use
JPS5829706A (en) * 1981-08-14 1983-02-22 Toko Yakuhin Kogyo Kk Antiphlogistic and analgesic agent for external use
GR81250B (en) * 1983-12-22 1985-11-19 American Home Prod Menthol enhancement of transdermal drug delivery
JPS63179820A (en) * 1987-01-22 1988-07-23 Kao Corp Suppository composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9104733A1 *

Also Published As

Publication number Publication date
GB9020874D0 (en) 1990-11-07
CA2067131A1 (en) 1991-03-27
JPH05502440A (en) 1993-04-28
GB8921710D0 (en) 1989-11-08
WO1991004733A1 (en) 1991-04-18
AU6504190A (en) 1991-04-28
GB2239600A (en) 1991-07-10

Similar Documents

Publication Publication Date Title
EP0151953B1 (en) Topical drug release system
EP0072462B1 (en) Pharmaceutical preparations
KR101793707B1 (en) Non-steroidal anti-inflammatory solution comprising diclofenac acid, lidocaine and acid stabilizer
EP0493496A1 (en) Ibuprofen triturates and topical compositions containing same
US4794117A (en) Process for solubilizing active ingredients and the thus-obtained pharmaceutical compositions
PL177592B1 (en) Novel composition
US20040063794A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
WO1991008733A1 (en) Stable cream and lotion bases for lipophilic drug compositions
US20060241175A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
JPS5815909A (en) Antimycotic agent for external use
JP4195178B2 (en) Anti-inflammatory analgesic topical
JPS60209515A (en) Anti-inflammatory and analgesic cream agent
JPH0676328B2 (en) Steroid cream formulation
JP4066466B2 (en) Ointment containing sugar alcohols
WO2004030665A1 (en) Transparent gel composition, for the administration of diclofenac sodium through the skin
US5128135A (en) Percutaneous or trans-mucosal absorption enhancers, preparations containing the enhancers, and a method of preparing thereof
JPH0413624A (en) Pyroxycam-containing pharmaceutical composition for topical application
GB2236250A (en) Ibuprofen solutions and topical compositions
JPS62223118A (en) Cream composition for external use
GB2327041A (en) Topical Analgesic Composition
RU2157683C2 (en) Anti-inflammatory preparation for topical use
JPH0725674B2 (en) Anti-inflammatory analgesic external cream preparation
TR2021007476A2 (en) TOPICAL COMPOSITIONS CONTAINING INDOMETHACINE IN COMBINATION WITH MUSCLE RELAXANT AGENTS
JPH10182458A (en) Indomethacin-containing preparation composition for external use
RU2148998C1 (en) Pharmaceutical or veterinary composition (variants) and method of composition preparing

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920323

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19930405